- Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. Oberic, L., Viret, F., Baey, C., Ychou, M., Bennouna, J., Adenis, A., Peiffert, D., Mornex, F., Pignon, J.P., Celier, P., Berille, J., Ducreux, M. Radiat. Oncol (2011)